Swipe om te navigeren naar een ander artikel
To evaluate psychometric properties of the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) questionnaire, a 47-item disease-specific instrument evaluating Health-Related Quality of Life (HRQL) in human immunodeficiency virus (HIV)-infected patients.
Treatment-experienced HIV-infected patients from two clinical programmes (N = 565; N = 1,096) completed the FAHI at Baseline and after 24 weeks of treatment. Psychometric properties of the FAHI were assessed in both trial populations, including minimal important differences (MIDs) calculations. Links between HRQL assessed by FAHI Total score, and biological endpoints were explored by regression analysis and mean score comparisons.
Cronbach’s alphas ranged from 0.72 to 0.94. Most items met convergent and discriminant validity criteria. Better FAHI scores were seen for patients in earlier HIV stages. Responsiveness was demonstrated with changes in FAHI scores significantly linked to change in EQ-5D score. Depending on methods used, MIDs ranged from 3.2 to 14 for FAHI Total score. Small association was found between FAHI Total score and CD4 count and viral load (r-square < 3%). Mean changes in FAHI scores were not statistically related to viral response.
The FAHI demonstrated acceptable psychometric properties in two independent populations. HRQL assessment enabled detection of changes in patients’ health status not revealed by traditional efficacy endpoints.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Detels, R., Munoz, A., McFarlane, G., Kingsley, L. A., Margolick, J. B., Giorgi, J., et al. (1998). Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. The Journal of American Medical Association, 280(17), 1497–1503. CrossRef
Palella, F. J., Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. The New England Journal of Medicine, 338(13), 853–860. CrossRefPubMed
Montessori, V., Press, N., Harris, M., Akagi, L., & Montaner, J. S. (2004). Adverse effects of antiretroviral therapy for HIV infection. Canadian Medical Association Journal, 170(2), 229–238. PubMed
Chassany, O., Sagnier, P., Marquis, P., Fullerton, S., Aaronson, N., & ERIQA Group. (2002). Patient-reported outcomes: The example of health-related quality of life—A European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Information Journal, 36, 209–238.
Lin, M. K., Wu, A. W., & Revicki, D. A. (2002). Incorporating quality of life measures in HIV clinical trials. HIC Clinical Trials, 3(3), 202–218. CrossRef
World Health Organisation. (1948). WHO definition of health. http://www.who.int/about/definition/en/print.html. Accessed 6 October 2009.
Cella, D. F., Tulsky, D. S., Gray, G., et al. (1993). The functional assessment of cancer therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570–579. PubMed
Berzon, R. A., & Lenderking, W. R. (1998). Evaluating the outcomes of HIV disease: Focus on health status measurement. A publication for members of medical outcomes trust, 3(4).
Grossman, H. A., Sullivan, P. S., & Wu, A. W. (2003). Quality of life and HIV: Current assessment tools and future directions for clinical practice. AIDS Read, 13(12), 583–587. PubMed
Lazzarin, A., Campbell, T., Clotet, B., Johnson, M., Katlama, C., Moll, A., et al. (2007). Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, 370(9581), 39–48. CrossRefPubMed
Madruga, J. V., Cahn, P., Grinsztejn, B., Haubrich, R., Lalezari, J., Mills, A., et al. (2007). Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, 370(9581), 29–38. CrossRefPubMed
Eremenco, S. L., Cella, D., & Arnold, B. J. (2005). A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Evaluation & The Health Professions, 28(2), 212–232. CrossRef
Cronbach, L. J. (1951). Coefficient alpha and the internal structure of tests. Psychometrika, 16(3), 297–334. CrossRef
Nunnally, J. C., & Bernstein, I. H. (1994). Psychometric theory. New York: McGraw-Hill Inc.
Hays, R. D., Anderson, R. T., & Revicki, D. A. (1998). Assessing reliability and validity of measurement in clinical trials. In M. J. Staquet, R. D. Hays, & P. M. Fayers (Eds.), Quality of life assessment in clinical trials: methods and practice (pp. 169–182). New-York, Tokyo: Oxford.
Hays, R. D., & Hayashi, T. (1990). Beyond internal consistency reliability: rationale and user’s guide for Multitrait analysis program on the microcomputer. Behavior Research, Methods, Instruments and Computers, 22, 167–175.
Cohen, J. (1977). Statistical power analysis for the behavioral sciences. New York: Academic Press.
Sloan, J. A., Symonds, T., Vargas-Chanes, D., & Fridley, B. (2003). Practical guidelines for assessing the clinical significance of health related quality of life changes within clinical trials. Drug Information Journal, 37, 23–31.
Yost, K. J., Sorensen, M. V., Hahn, E. A., Glendenning, G. A., Gnanasakthy, A., & Cella, D. (2005). Using multiple anchor- and distribution-based estimates to evaluate clinically meaningful change on the functional assessment of cancer therapy-biologic response modifiers (FACT-BRM) instrument. Value in Health, 8(2), 117–127. CrossRefPubMed
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH). (2009). Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed 20 May 2010.
Revicki, D. A., Wu, A. W., & Murray, M. I. (1995). Change in clinical status, health status, and health utility outcomes in HIV-infected patients. Medical Care, 33(4 Suppl), AS173–AS182. PubMed
- Psychometric evaluation of the functional assessment of HIV Infection (FAHI) questionnaire and its usefulness in clinical trials
- Springer Netherlands